Illumina's net margin currently stands at 16.4%, which is lower than the 18.5% average across the broader Healthcare Equipment & Supplies sector. However, Illumina's track record of innovation and its leading market position suggest the company has the potential to drive margin expansion over the next 12-18 months. Illumina's research and development spending has increased by 23.4% year-over-year, indicating a robust pipeline of new product introductions. These new product launches, combined with Illumina's scale advantages and ongoing cost optimization initiatives, should enable the company to expand its gross and operating margins. Over the past 3 years, Illumina has improved its ROIC from 10.8% to 12.1%, demonstrating the company's ability to generate stronger returns on its capital investments. The combination of new product momentum, efficiency gains, and ROIC expansion positions Illumina well to capture margin upside in the coming quarters. I expect Illumina's net margin to rise from the current 16.4% to the 18-19% range over the next 12-18 months, as the company benefits from its innovative pipeline, cost optimization efforts, and scale advantages. This margin expansion, coupled with Illumina's leadership in the high-growth DNA sequencing market, makes the stock an attractive investment opportunity at the current valuation.

Research these companies